Safety Analyses of the Phase 3 VISION Trial of [ <SUP>177 </SUP>Lu]Lu-PSMA-617 in Patients with Metastatic Castration-resistant Prostate Cancer
Date
2024-04-01ICR Author
Author
Chi, KN
Armstrong, AJ
Krause, BJ
Herrmann, K
Rahbar, K
de Bono, JS
Adra, N
Garje, R
Michalski, JM
Kempel, MM
Fizazi, K
Morris, MJ
Sartor, O
Brackman, M
Desilvio, M
Wilke, C
Holder, G
Tagawa, ST
Type
Journal Article
Metadata
Show full item recordCollections
Subject
Science & Technology
Life Sciences & Biomedicine
Urology & Nephrology
Metastatic castration-resistant
prostate cancer
Radioligand therapy
Lu-177-PSMA-617
Treatment-emergent adverse
events
Treatment exposure
RADIOLIGAND THERAPY
OPEN-LABEL
MULTICENTER
EFFICACY
Research team
PrCa Targeted Therapy
Language
eng
Date accepted
2023-12-11
License start date
2024-04-01
Citation
European Urology, 2024, 85 (4), pp. 382 - 391
Publisher
ELSEVIER